Cancer clinical trials in the region Île-de-France
693 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Chronic myeloid leukemia (CML)
#NCT02889003
Required number of previous lines of therapy
1
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
BCR-ABL
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
3 recruiting sites
Hôpital de Versailles
Phase 2
Acute leukemia
#NCT07007052
#2024-511003-42-00
Required histologic types
Blastic plasmacytoid dendritic cell neoplasm (BPDC...
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
French Innovative Leukemia Organisation (FILO)
Phase 2
Lymphoma
#NCT05139017
#2022-502646-27-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Car-T
Autologous stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 2
Lymphoma
#NCT04984837
#2024-513252-15-00
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
1 recruiting site
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lung cancer
#NCT07098338
#2025-524843-11-00
Sous étude 1 et 2
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Radiotherapy
1 recruiting site
AstraZeneca
Phase 2
Lung cancer
#NCT07098338
#2025-524843-11-00
Sous-étude 3
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
AstraZeneca
Phase 2
Sarcoma and GIST
#NCT05182164
#2023-509496-16-00
Ostéosarcome osseux ou extra-squelettique
Required histologic types
Bone sarcoma
Required histologic sub types
Osteosarcoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
6 recruiting sites
Institut Bergonié
Phase 2
Sarcoma and GIST
#NCT05182164
#2023-509496-16-00
Sarcome d’Ewing
Required histologic types
Bone sarcoma
Required histologic sub types
Ewing tumor
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
6 recruiting sites
Institut Bergonié, Merck Sharp & Dohme LLC
Phase 2
Sarcoma and GIST
#NCT05182164
#2023-509496-16-00
Sarcome pléomorphe indifférencié avancé
Required histologic types
Soft tissue sarcoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
6 recruiting sites
Institut Bergonié
Phase 2
Skin cancer
#NCT06172478
#2023-507641-29-00
Melanoma Cohort
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma
Lentigo maligna melanoma
Superficial spreading melanoma
Acral lentiginous melanoma
Achromic melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo